Thymalin Benefits for Immune Function
Thymalin is the thymus-derived bioregulator in Khavinson's family of peptides. It directly targets the thymus — the organ responsible for producing and educating T-cells — and restores aspects of immune function that decline as the thymus involutes (shrinks) with age. In Khavinson's studies, Thymalin is associated with reduced mortality and improved cancer surveillance markers in elderly populations.
Thymalin — Research Grade
Available from Base Peptides for research applications.
Research context. Thymalin has registered medical status in Russia where it is used clinically. It is a research compound in most other jurisdictions. This article is for educational purposes.
The thymus is the primary factory for T-lymphocytes — the immune cells responsible for adaptive immunity (identifying and destroying foreign pathogens and cancer cells). It grows during childhood and begins declining at puberty, progressively replaced by fatty tissue. This process is called thymic involution.
| Age | Thymus Size | Immune Function |
|---|---|---|
| Birth–puberty | Maximum size (~37g at peak) | Full thymic output — producing and educating T-cells in very high numbers |
| 20s–30s | ~50% original mass | Reduced but still substantial T-cell output |
| 40s–50s | ~20% original mass | Significant decline in naïve T-cell production |
| 60s+ | ~5–10% original mass | Severely reduced output; mostly replaced by fat tissue |
T-lymphocyte count
Thymalin restores T-cell production capacity — critical as thymus activity declines with age
NK cell activity
Natural killer cells are the primary defence against cancer cells; Thymalin improves their function in elderly subjects
Thymulin (endogenous)
Thymulin is the thymus's own peptide; Thymalin supplementation appears to stimulate its endogenous production
IL-2 production
Interleukin-2 drives T-cell proliferation; IL-2 decline is a key marker of immune ageing
Inflammatory markers (IL-6, CRP)
Chronic low-grade inflammation (inflammageing) is reduced in subjects receiving Thymalin cycles
10 mg/day for 10 days, administered subcutaneously or intramuscularly
1–2 cycles per year, typically spring and/or autumn
Commonly paired with Epitalon in longevity protocols — Thymalin handles immune restoration while Epitalon handles telomere/pineal support
Immune panel (CBC with differential) before and 4–6 weeks after cycle to assess T-cell response
The leading causes of death in people over 65 are cancer, cardiovascular disease, and infection — all diseases where immune function is a primary determinant of outcome. A well-functioning immune system provides cancer surveillance (catching early-stage malignant cells), infection resistance, and reduced chronic inflammation that drives cardiovascular damage.
Khavinson's landmark 12-year study showed elderly subjects receiving annual Thymalin cycles had a statistically significant reduction in mortality — and the mortality reduction was most pronounced for cancer and infection-related causes. This is not coincidental — it is mechanistically coherent with Thymalin's immunomodulatory action.
In a longevity protocol, Thymalin addresses the immune arm of ageing while Epitalon addresses the telomere/pineal arm. These are complementary, not redundant.
Peptide Detail Profiles
Bioregulator Peptides Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →